首页> 外文学位 >Adaptive radiation therapy of prostate cancer.
【24h】

Adaptive radiation therapy of prostate cancer.

机译:前列腺癌的适应性放射治疗。

获取原文
获取原文并翻译 | 示例

摘要

ART is a close-loop feedback algorithm which evaluates the organ deformation and motion right before the treatment and takes into account dose delivery variation daily to compensate for the difference between planned and delivered dose. It also has potential to allow further dose escalation and margin reduction to improve the clinical outcome. This retrospective study evaluated ART for prostate cancer treatment and radiobiological consequences. An IRB approved protocol has been used to evaluate actual dose delivery of patients with prostate cancer undergoing treatment with daily CBCT.The dose from CBCT was measured in phantom using TLD and ion chamber techniques in the pelvic scan setting. There were two major findings from the measurements of CBCT dose: (1) the lateral dose distribution was not symmetrical, with Lt Lat being &sim40% higher than Rt Lat and (2) AP skin dose varies with patient size, ranging 3.2--6.1 cGy for patient's AP separation of 20--33 cm (the larger the separation, the less the skin dose) but lateral skin doses depend little on separations.Dose was recalculated on each CBCT set under the same treatment plan. DIR was performed between SIM-CT and evaluated for each CT sets. Dose was reconstructed and accumulated to reflect the actual dose delivered to the patient. Then the adaptive plans were compared to the original plan to evaluate tumor control and normal tissue complication using radiobiological model. Different PTV margins were also studied to access margin reduction techniques. If the actual dose delivered to the PTV deviated significantly from the prescription dose for the given fractions or the OAR received higher dose than expected, the treatment plan would be re-optimized based on the previously delivered dose. The optimal schedule was compared based on the balance of PTV dose coverage and inhomogeneity, OAR dose constraints and labor involved.DIR was validated using fiducial marker position, visual comparison and UE. The mean and standard deviation of markers after rigid registration in L-R direction was 0 and 1 mm. But the mean was 2--4 mm in the A-P and S-I direction and standard deviation was about 2 mm. After DIR, the mean in all three directions became 0 and standard deviation was within sub millimeter. UE images were generated for each CT set and carefully reviewed in the prostate region. DIR provided accurate transformation matrix to be used for dose reconstruction.The delivered dose was evaluated with radiobiological models. TCP for the CTV was calculated to evaluate tumor control in different margin settings. TCP calculated from the reconstructed dose agreed within 5% of the value in the plan for all patients with three different margins. EUD and NTCP were calculated to evaluate reaction of rectum to radiation. Similar biological evaluation was performed for bladder. EUD of actual dose was 3%--9% higher than that of planned dose of patient 1--3, 11%--20% higher of patient 4--5. Smaller margins could not reduce late GU toxicity effectively since bladder complication was directly related to Dmax which was at the same magnitude in the bladder no matter which margin was applied.Re-optimization was performed at the 10th, 20th , 30th, and 40th fraction to evaluate the effectiveness to limit OAR dose while maintaining the target coverage. Reconstructed dose was added to dose from remaining fractions after optimization to show the total dose patient would receive. It showed that if the plan was re-optimized at 10th or 20th fraction, total dose to rectum and bladder were very similar to planned dose with minor deviations. If the plan was re-optimized at the 30th fraction, since there was a large deviation between reconstructed dose and planned dose to OAR, optimization could not limit the OAR dose to the original plan with only 12 fractions left. If the re-optimization was done at the 40th fraction, it was impossible to compensate in the last 2 fractions. Large deviations of total dose to bladder and rectum still existed while dose inhomogeneity to PTV was significantly increased due to hard constraints set in the optimization to reduce OAR dose.In summary, ART did not show improvements in TCP if the patient was setup with CBCT. However, EUD of rectum and bladder was increased significantly due to tissue deformation which varied daily. With the power of ART, margins added to the CTV could be further reduced to preserve critical organs surrounding the target. (Abstract shortened by UMI.)
机译:ART是一种闭环反馈算法,可在治疗之前评估器官变形和运动,并每天考虑剂量输送变化,以补偿计划剂量和输送剂量之间的差异。它还有潜力进一步提高剂量和减少切缘,以改善临床疗效。这项回顾性研究评估了ART治疗前列腺癌和放射生物学的后果。已使用IRB批准的方案评估每日接受CBCT治疗的前列腺癌患者的实际剂量递送。在盆腔扫描设置中使用TLD和离子室技术在幻影中测量CBCT的剂量。 CBCT剂量的测量有两个主要发现:(1)横向剂量分布不对称,Lt Lat比Rt Lat高&sim40%;(2)AP皮肤剂量随患者大小而变化,范围为3.2--6.1患者AP间隔为20--33厘米的cGy(间隔越大,皮肤剂量越少),但外侧皮肤剂量对间隔的依赖性很小。在相同的治疗计划下,对每个CBCT组重新计算剂量。在SIM-CT之间执行DIR,并针对每个CT组进行评估。剂量被重建并累积以反映输送给患者的实际剂量。然后将适应性计划与原始计划进行比较,以使用放射生物学模型评估肿瘤控制和正常组织并发症。还研究了不同的PTV边距,以降低边距。如果对于给定的分数,交付给PTV的实际剂量明显偏离处方剂量,或者OAR收到的剂量比预期的要高,则将根据先前交付的剂量重新优化治疗计划。根据PTV剂量覆盖率和不均一性,OAR剂量限制和所涉及的劳动之间的平衡来比较最佳计划表。使用基准标记位置,视觉比较和UE来验证DIR。在L-R方向上刚性对齐后,标记的平均和标准偏差为0和1 mm。但平均值在A-P和S-I方向上为2--4毫米,标准偏差约为2毫米。 DIR之后,所有三个方向的平均值变为0,标准偏差在1毫米以内。为每个CT集生成UE图像,并在前列腺区域仔细检查。 DIR提供了准确的转换矩阵以用于剂量重建。使用放射生物学模型评估了所输送的剂量。计算用于CTV的TCP,以评估不同裕度设置下的肿瘤控制。对于三个具有不同余量的患者,从重建剂量计算得出的TCP均应在计划值的5%内。计算EUD和NTCP以评估直肠对放射线的反应。对膀胱进行了相似的生物学评估。 EUD的实际剂量比患者1--3的计划剂量高3%-9%,患者4--5的计划剂量高11%-20%。较小的边界不能有效降低晚期GU毒性,因为无论采用哪种边界,膀胱并发症均与Dmax直接相关,Dmax在膀胱内的大小相同。在10、20、30和40分数进行重新优化在限制目标覆盖率的同时评估限制OAR剂量的有效性。优化后,将重构的剂量添加到剩余部分的剂量中,以显示患者将接受的总剂量。结果表明,如果在第10或20部分重新优化计划,则直肠和膀胱的总剂量与计划剂量非常相似,只有很小的偏差。如果在第30部分重新优化计划,由于重建剂量与计划的OAR剂量之间存在较大偏差,因此优化不能将OAR剂量限制在原始计划中,只剩下12个部分。如果在第40个分数处进行了重新优化,则无法在最后两个分数中进行补偿。总的来说,膀胱和直肠的总剂量仍存在较大偏差,而由于优化中为降低OAR剂量而设置的严格限制,导致PTV的剂量不均匀性显着增加。总之,如果患者使用CBCT,则ART在TCP方面无改善。然而,由于组织变形每天都会变化,因此直肠和膀胱的EUD显着增加。借助ART的力量,可以进一步减少CTV的利润,以保护目标周围的重要器官。 (摘要由UMI缩短。)

著录项

  • 作者

    Wen, Ning.;

  • 作者单位

    Wayne State University.;

  • 授予单位 Wayne State University.;
  • 学科 Physics Radiation.Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 124 p.
  • 总页数 124
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号